Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes

Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes

Tao Wang,1 Yang Liu,1 Bin Zhou,1 Zhi Wang,1 Naichao Liang,1 Yundong Zhang,1 Zhouhuan Dong,2 Jie Li2 1Department of Thoracic Surgery, 2Department of Pathology, People’s Liberation Army General Hospital, Beijing, People’s Republic of China Purpose: Epidermal growth factor recepto...

Full description

Bibliographic Details
Main Authors:	Wang T, Liu Y, Zhou B, Wang Z, Liang NC, Zhang YD, Dong ZH, Li J
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-03-01
Series:	OncoTargets and Therapy
Subjects:	Non-small cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitor neoadjuvant
Online Access:	https://www.dovepress.com/effects-of-icotinib-on-early-stage-non-small-cell-lung-cancer-as-neoad-peer-reviewed-article-OTT

Similar Items

Complete remission through icotinib treatment in Non-small cell lung cancer epidermal growth factor receptor mutation patient with brain metastasis: A case report
by: Wang Tao, et al.
Published: (2016-01-01)

Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report
by: Caroline Y. Chen, et al.
Published: (2021-04-01)

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials
by: Li Sun, et al.
Published: (2021-01-01)

Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
by: Laksmi Wulandari, et al.
Published: (2018-07-01)

Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment
by: Liang H, et al.
Published: (2018-09-01)

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
by: Lee CS, et al.
Published: (2020-10-01)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
by: Sojung Park, et al.
Published: (2021-01-01)

Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors
by: Yue-Yun Chen, et al.
Published: (2021-08-01)

Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation
by: Patel N, et al.
Published: (2017-06-01)

Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
by: Shouzheng Wang, et al.
Published: (2021-10-01)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
by: Shih-Chieh Chang, et al.
Published: (2011-06-01)

Prevalence and outcome of epidermal growth factor receptor mutations in non-squamous non-small cell lung cancer patients
by: Rajesh Kota, et al.
Published: (2015-01-01)

Efficacy of pemetrexed-based regimens in advanced non–small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review
by: Han BH, et al.
Published: (2018-04-01)

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
by: Connor O’Leary, et al.
Published: (2020-09-01)

Clinical Study of Erlotinib in the Treatment of Patients with Advanced Stage Non-small Cell Lung Cancer
by: Renhua GUO, et al.
Published: (2009-12-01)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib
by: Sami Morin-Ben Abdallah, et al.
Published: (2017-05-01)

Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation—A Case Report and a Review of the Literature
by: Izumi Sato, et al.
Published: (2020-08-01)

Progress toward resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitor
by: Zhang Lingling, et al.
Published: (2016-01-01)

Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer
by: Zhang H
Published: (2016-11-01)

Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study
by: John WC Chang, et al.
Published: (2015-06-01)

Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection
by: Fan L, et al.
Published: (2017-01-01)

Application of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as the First-line Therapy in Patients with Advanced Non-small Cell Lung Cancer
by: Chunsun LI, et al.
Published: (2010-01-01)

Predictive value of clinical parameters in responses to epidermal growth factor-tyrosine kinase inhibitors as first-line therapy for stage Ⅳ non-small cell lung cancer
by: ZHENG Linpeng, et al.
Published: (2019-02-01)

Research Progress on Resistance Mechanisms of Epidermal Growth Factor Receptor  Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
by: Yuan LI, et al.
Published: (2012-02-01)

Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
by: Lianfang NI, et al.
Published: (2018-02-01)

Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review
by: Emma-Anne Karlsen, et al.
Published: (2021-05-01)

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
by: Tristan A. Barnes, et al.
Published: (2017-05-01)

Clinical Observation of EGFR-TKI as A First-line Therapy on Advanced Non-small Cell Lung Cancer
by: Jianjie LI, et al.
Published: (2012-05-01)

Clinical Experience with First-generation Epidermal Growth Factor Receptor  Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients  with Brain Metastasis
by: Huixing DONG, et al.
Published: (2017-02-01)

Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management
by: Sathishbabu Paranthaman, et al.
Published: (2020-12-01)

De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma
by: Takumi Fujiwara, et al.
Published: (2020-10-01)

Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review
by: Takuma Imakita, et al.
Published: (2019-01-01)

Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
by: Soomin Ahn, et al.
Published: (2016-07-01)

Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations
by: Fang Wang, et al.
Published: (2019-03-01)

Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
by: Ling-Ling Kong, et al.
Published: (2017-12-01)

Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
by: Ming-Ju Tsai, et al.
Published: (2018-11-01)

Alkaline phosphatase flare phenomenon following epidermal growth factor receptor-tyrosine kinase inhibitor treatment of non-small cell lung cancer: Report of a case and case review
by: Yuko Yasuda, et al.
Published: (2014-01-01)

Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
by: Yung-Hung Luo, et al.
Published: (2015-09-01)

Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer
by: Gao Y, et al.
Published: (2015-12-01)

Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future
by: Walid Shalata, et al.
Published: (2021-08-01)